Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma

AstraZeneca

Status and phase: Completed; Phase 2

Conditions: Renal Cell Carcinoma

Treatments: Drug: Cediranib; Drug: Cediranib Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00423332

D8480C00030

EudraCT no. 2006-002455-33

Details and patient eligibility

About

Cediranib is being tested to assess its effectiveness on the growth of kidney cancer tumours and also how well it is tolerated.

Enrollment: 105 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Confirmation of metastatic or recurrent renal cell carcinoma

Exclusion criteria

• Certain types of previous anti-cancer therapy for Renal Cell Carcinoma
• Patients with type I insulin-dependent diabetes or poorly-controlled type II insulin-independent diabetes
• Patients with a history of poorly controlled high blood pressure

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

105 participants in 2 patient groups, including a placebo group

1

Placebo Comparator group

Description:

Cediranib placebo

Treatment:

Drug: Cediranib Placebo

2

Experimental group

Description:

Cediranib

Treatment:

Drug: Cediranib